# E-EDV-D682

Source: https://onco.cc/drugs/e-edv-d682/  
OnCo record `e-edv-d682` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

E-EDV-D682 is an experimental EDV nanocell (bacterial minicell) drug conjugate from Engeneic Pty in phase 2 trials for pancreatic ductal adenocarcinoma, aimed at EGFR.

## Summary

E-EDV-D682 (EDV-D682) is an EDV nanocell (bacterial minicell) drug conjugate developed by Engeneic Pty. Its target is EGFR (the sponsor names EGFR). The sponsor states: E-EDV-D682 packages the chemotherapeutic payload PNU-159682 inside a 400 nm, bacterially derived EnGeneIC EDV nanocell that is targeted to EGFR-expressing cancer cells via a bispecific antibody, delivering the payload directly into tumour cells. ClinicalTrials.gov describes the intervention as: E-EDV-D682 is a product based on the EnGeneIC EDV™ technology. EDVs are bacterially derived nanocells 400 nm in diameter that can be packaged with a range of different chemotherapeutic drugs and specifically targeted to cancer cell receptor. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, in pancreatic ductal adenocarcinoma. The largest, NCT07049055, plans to enrol 144 participants with primary completion expected 2028-09. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.

## Fields

- Kind: Treatment
- Status: phase-2
- Last checked: 2026-09-11
- Tags: pipeline; ctgov-ingest
- Code: EDV-D682
- Modality: EDV nanocell (bacterial minicell) drug conjugate
- Mechanism: E-EDV-D682 packages the chemotherapeutic payload PNU-159682 inside a 400 nm, bacterially derived EnGeneIC EDV nanocell that is targeted to EGFR-expressing cancer cells via a bispecific antibody, delivering the payload directly into tumour cells.

## Sources

- ClinicalTrials.gov: trials of E-EDV-D682: https://clinicaltrials.gov/search?intr=EDV-D682

## Connected records

- cancers: [Pancreatic ductal adenocarcinoma](https://onco.cc/cancers/pancreatic/)
- targets: [EGFR](https://onco.cc/targets/egfr/)
- companies: [EnGeneIC](https://onco.cc/companies/engeneic/)
- trials: [A Clinical Trial to Evaluate EDV Nanocell Therapy With Gemcitabine and Nab-paclitaxel in Pancreatic Cancer](https://onco.cc/trials/nct07049055/)

---
JSON: https://onco.cc/api/v1/entities/e-edv-d682.json